Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells

Por Holstein, Sarah A., Hohl, Raymond J.
Publicado em 2010

2011 Therapeutic Additions and Possible Deletions in Oncology

Por Holstein, Sarah A., Hohl, Raymond J.
Publicado no Clin Pharmacol Ther (2012)

Differential Activities of Thalidomide and Isoprenoid Biosynthetic Pathway Inhibitors in Multiple Myeloma Cells

Por Holstein, Sarah A., Tong, Huaxiang, Hohl, Raymond J.
Publicado no Leuk Res (2009)

Pleiotropic Effects of a Schweinfurthin on Isoprenoid Homeostasis

Por Holstein, Sarah A., Kuder, Craig H., Tong, Huaxiang, Hohl, Raymond J.
Publicado no Lipids (2011)

Calcium and P-glycoprotein independent synergism between schweinfurthins and verapamil

Por Sheehy, Ryan M, Kuder, Craig H, Bachman, Zoe, Hohl, Raymond J
Publicado no Cancer Biol Ther (2015)

Synthesis of isoprenoid bisphosphonate ethers through C–P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase

Por Zhou, Xiang, Reilly, Jacqueline E, Loerch, Kathleen A, Hohl, Raymond J, Wiemer, David F
Publicado em 2014

Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis

Por Reilly, Jacqueline E, Neighbors, Jeffrey D, Tong, Huaxiang, Henry, Michael D, Hohl, Raymond J
Publicado no Clin Exp Metastasis (2015)

A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro

Por Wasko, Brian M., Smits, Jacqueline P., Shull, Larry W., Wiemer, David F., Hohl, Raymond J.
Publicado em 2011

Functional Evaluation of a Fluorescent Schweinfurthin: Mechanism of Cytotoxicity and Intracellular Quantification

Por Kuder, Craig H., Sheehy, Ryan M., Neighbors, Jeffrey D., Wiemer, David F., Hohl, Raymond J.
Publicado em 2012

Fluorescent schweinfurthin B and F analogues with anti-proliferative activity

Por Topczewski, Joseph J., Kuder, Craig H., Neighbors, Jeffrey D., Hohl, Raymond J., Wiemer, David F.
Publicado em 2010

In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors

Por Reilly, Jacqueline E., Zhou, Xiang, Tong, Huaxiang, Kuder, Craig H., Wiemer, David F., Hohl, Raymond J.
Publicado no Biochem Pharmacol (2015)

3-deoxyschweinfurthin B lowers cholesterol levels by decreasing synthesis and increasing export in cultured cancer cell lines

Por Kuder, Craig H., Weivoda, Megan M., Zhang, Ying, Zhu, Junjia, Neighbors, Jeffrey D., Wiemer, David F., Hohl, Raymond J.
Publicado no Lipids (2015)

GBM-associated mutations and altered protein expression are more common in young patients

Por Ferguson, Sherise D., Xiu, Joanne, Weathers, Shiao-Pei, Zhou, Shouhao, Kesari, Santosh, Weiss, Stephanie E., Verhaak, Roeland G., Hohl, Raymond J., Barger, Geoffrey R., Reddy, Sandeep K., Heimberger, Amy B.
Publicado no Oncotarget (2016)

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

Por Miller, Antonius A., Murry, Daryl J., Owzar, Kouros, Hollis, Donna R., Kennedy, Erin B., Abou-Alfa, Ghassan, Desai, Apurva, Hwang, Jimmy, Villalona-Calero, Miguel A., Dees, E. Claire, Lewis, Lionel D., Fakih, Marwan G., Edelman, Martin J., Millard, Fred, Frank, Richard C., Hohl, Raymond J., Ratain, Mark J.
Publicado em 2009